Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. They will advance a range of conjugates, unlimited by indication, using their own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Description

People (12)

Jobs (0)

Other offices